Pular para o conteúdo
Merck
  • Development and validation of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous determination of bupropion, quetiapine and escitalopram in human plasma.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous determination of bupropion, quetiapine and escitalopram in human plasma.

Biomedical chromatography : BMC (2014-09-30)
Semin Park, Chul-Soo Park, Sung Joong Lee, Boseok Cha, Young Ah Cho, Yi Song, Eun Ae Yu, Gon-Sup Kim, Jong Sung Jin, A M Abd El-Aty, H A El-Banna, Ahmet Hacımüftüoğlu, Jae-Han Shim, Sung Chul Shin
RESUMO

In the present study, an effective high performance liquid chromatography-tandem mass spectrometric (HPLC/MS/MS) method was developed and validated to simultaneously determine bupropion (BUP), quetiapine (QUE) and escitalopram (ESC) in human plasma using carbidopa as the internal standard. Chromatographic separation was achieved on a Waters Sun Fire C18 column using reversed-phase chromatography. The MS/MS experiment was performed in positive ion multiple reaction monitoring mode to produce product ions of m/z 240.3 → 184.2 for BUP, 384.2 → 253.1 for QUE, 325.3 → 109.3 for ESC and 227.2 → 181.2 for the internal standard. The method showed good linearity (R(2)  ≥ 0.997), precision (relative standard deviation ≤7.5%), satisfactory intra- and interday accuracy (88.4-113.0%) and acceptable extraction recovery (87.2-115.0%), matrix effect (84.5.5-108.7%) and stability (92.3-103.5%). The method was successfully applied to determine the concentrations of BUP, QUE and ESC in human plasma samples.

MATERIAIS
Número do produto
Marca
Descrição do produto

Carbidopa, European Pharmacopoeia (EP) Reference Standard